ClinicalTrials.gg
Not yet recruitingNCT07049731Updated Jul 9, 2025

Improvement of Skeletal and Muscle Health in Patients With Sarcopenia by Protein Powder With Resistance Exercise

An interventional study of Protein powder intervention and Resistance exercise intervention in Sarcopenia, sponsored by Weiwei Ma. Not yet recruiting at 1 site in China. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Weiwei Ma · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Sarcopenia with a site in China — 47 open to participants now, 52 under way, 4 of them phase 3. Sarcopenia · China.

Planned enrollment
10th of 52
224 · median 110
Started
2025
with 10 others
No phase
42 of 83
20 open now
Primary completion
2026-12
later than 21 of 51 live
Registered
55th of 83
by date

Among the 83 studies in Sarcopenia with a site in China, this one is the 10th largest by planned enrollment of the 52 interventional ones that give a count, is one of 11 that started in 2025, is one of 42 with no phase, reaches primary completion later than 21 of the 51 other live ones, and was the 55th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

47 of the 83 studies in Sarcopenia with a site in China are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Sarcopenia with a site in China, or all of them as a file.
02

Study summary

Sarcopenia is an age-related progressive skeletal muscle disease, the prevalence of which is increasing year by year with the aging of China's population, seriously affecting the health and quality of life of the elderly. Relevant studies have shown that protein intake in combination with resistance exercise can significantly improve muscle mass and function, and the effect is superior to that of a single intervention. In addition, ingredients such as vitamin D, N-acetylglucosamine, sodium hyaluronate, and taurine can further promote muscle health by regulating metabolism and inflammation levels. However, there are relatively few intervention studies combining the above nutrients with resistance exercise in patients with sarcopenia. Therefore, this study intends to use protein powder containing milk protein, vitamin D, N-acetylglucosamine, sodium hyaluronate, taurine and other ingredients, combined with low-intensity resistance exercise, to intervene in the middle-aged and elderly patients with sarcopenia, and to explore and observe the effects on muscle mass, bone density, intestinal health and other indexes of patients with sarcopenia, with the aim of providing a more accurate nutritional and exercise intervention program for the prevention and treatment of sarcopenia.

03

Conditions studied

  • Sarcopenia

Browse trials for

04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the diagnostic criteria for sarcopenia AWGS 2019

    1. Grip strength less than 28.0 kg for males and less than 18.0 kg for females
    2. 6-meter stride speed less than 1.0 m/s or 5-repetition sit-up test time ≥ 12 seconds or SPPB ≤ 9 points.
    3. Bioelectrical Impedance Analysis (BIA) less than 7.0 kg/m² for males and 5.7 kg/m² for females or Dual-energy X-ray absorptiometry (DXA) less than 7.0 kg/m² for males and 5.4 kg/m² for females;
  • Age between 35-75 years old with high compliance;
  • Complete clinical data;
  • Voluntary participation in the program with and signing of the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • A clear history of allergy to protein powder in the past 6 months, or the presence of diarrhea symptoms and the frequency of ≥ 7 days / month, the duration of more than 2 weeks;
  • Major physical diseases (diabetes with serious complications, malignant tumors, serious cardiovascular disease, neurological diseases or other diseases that may affect the effectiveness of exercise and nutritional interventions, etc.);
  • The past three months, new fractures and recently underwent joint replacement surgery patients;
  • Suffering from congenital bone or muscle diseases;
  • The simultaneous existence of other comorbidities affecting muscle metabolism, such as malignant tumors, liver disease, severe organ insufficiency such as nephrotic syndrome, renal failure and other diseases that may affect protein metabolism;
  • Participating in other clinical trials patients;
  • With sensory disabilities or other reasons significantly affecting the collection of data, such as severe deafness, blindness, mental disorders, etc.;
  • The researchers The researchers believe that other reasons are not suitable for clinical trials.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
224 participants (estimated)

Study arms

  • Placebo comparator
    Placebo control group

    Dietary Supplement: Placebo control

  • Experimental
    Protein powder intervention group

    Dietary Supplement: Protein powder intervention

  • Experimental
    Resistance exercise+placebo control group

    Behavioral: Resistance exercise intervention · Dietary Supplement: Placebo control

  • Experimental
    Resistance exercise + protein powder intervention group

    Dietary Supplement: Protein powder intervention · Behavioral: Resistance exercise intervention

Interventions

  • Dietary supplementProtein powder intervention

    On the basis of a balanced diet, 2 sachets of Aiben Leap Protein Nutritional Powder (each sachet containing 6g of milk protein) were supplemented daily.

  • BehavioralResistance exercise intervention

    Low-intensity resistance training was conducted 3 times a week.

  • Dietary supplementPlacebo control

    placebo was given and an individualized balanced dietary plan based on the Dietary Guidelines for Chinese Residents was provided.

06

What researchers measure

Primary outcomes

  1. Extremity Skeletal Muscle Mass Index (ASMI)

    ASM was measured using BIA, ASMI=ASM/height (m)\^2.

    Time frame: Baseline, month 3, month 6

  2. Handgrip strength

    Maximum force grip was held for 3 seconds, the right and left hands were measured alternately, 3 measurements were taken in each hand, and the maximum value was taken.

    Time frame: Baseline, month 3, month 6

  3. 6m walking speed

    Let the tester start from the starting point, walk 6 meters at normal walking speed, stop when reaching the end point, record the time used, and calculate the 6m walking speed according to the time used and the distance of 6 meters.

    Time frame: Baseline, month 3, month 6

  4. Chair sitting and standing test

    The subject sat in the center of the chair, crossed his/her arms in front of his/her chest, and after hearing the command "start", he/she completed 5 consecutive times of standing up and sitting down, and recorded the total time in seconds.

    Time frame: Baseline, month 3, month 6

  5. Simple Physical Performance Battery (SPPB)

    The SPPB consists of 3 test items, each item is scored out of 4 points, and the total score is 12.

    Time frame: Baseline, month 3, month 6

Secondary outcomes

  1. General survey

    Using a questionnaire designed by the research team and validated by the previous study, the survey covered the age, gender, ethnicity, marital status, occupation, education level, place of residence, household income, living status (living alone and with family), dietary habits and application of nutritional supplements, lifestyle (smoking, drinking, and physical activity), family history, and chronic diseases (hypertension, diabetes, etc.) of the study participants, Hyperlipidemia, etc.)

    Time frame: Baseline, month 6

  2. Height

    Measure the height of the subjects

    Time frame: Baseline, month 3, month 6

  3. Weight

    Measure the weight of the subjects

    Time frame: Baseline, month 3, month 6

  4. Body Mass Index(BMI)

    Calculate BMI using height and weight , BMI=weight/(height)\^2

    Time frame: Baseline, month 6

  5. Waist circumference, hip circumference, and waist to hip ratio

    Measure the waist and hip circumference of the subjects and calculate the waist to hip ratio (waist circumference/hip circumference).

    Time frame: Baseline, month 3, month 6

  6. Body composition

    Using a human body composition analyzer to detect indicators such as total score, visceral fat area, body segment fat and basal metabolic rate, body cell mass, and limb skeletal muscle mass index.

    Time frame: Baseline, month 6

  7. Assessment of ability to perform activities of daily living

    The ADL was assessed using the Activity of Daily Living Scale (ADL), which consists of 10 items, including eating, bathing, grooming, dressing, bowel control, urination control, toileting, bed and chair transfers, walking, and walking up and down stairs. The total score is 100, with a score of more than 60 indicating mild functional impairment but basic self-care in daily life; a score of 60-41 indicating moderate functional impairment and need for some assistance in daily life; a score of 40-21 indicating severe functional impairment and obvious need for dependence on others in daily life; and a score of less than 20 indicating complete disability and total dependence on others in daily life.

    Time frame: Baseline, month 3, month 6

  8. Sleep assessment

    The PSQI (Pittsburgh Sleep Quality Index) questionnaire was used to assess the quality of the subjects' sleep during the last 1 month. It consists of 19 self-assessment and 5 other-assessment entries, of which the 19th self-assessment and 5 other-assessment entries are not involved in scoring. The cumulative score of each component is the total PSQI score, which ranges from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: Baseline, month 3, month 6

  9. Analysis of dietary intake

    The 3-day, 24-hour dietary recall method was used to investigate the subjects' dietary intake. The survey process was supplemented with tools such as the "Retrospective Dietary Survey Auxiliary Chart" to help the subjects accurately recall their dietary intake. Based on the Standardized Version of the Chinese Food Composition Table (6th Edition), the energy and various types of protein, fat and carbohydrate intake of the population were calculated, and for the missing data in the Chinese Food Composition Table, the United States Department of Agriculture Food Composition Table was used to supplement the data, so as to build up a comprehensive database of dietary intake. The analysis of dietary intake included the intake of total fat, total protein, total carbohydrates and energy and its percentage in the total energy intake.

    Time frame: Baseline, month 6

  10. Assessment of overall cognitive functioning

    Subjects were assessed for overall cognitive functioning using the Montreal cognitive assessment (MoCA) scale out of 30, which contains cognitive functioning tests in multiple dimensions of visuospatial and executive functioning, naming, memory, attention, language, abstraction, delayed recall, and orientation.The normal threshold is usually ≥ 26 points, 21-25 points indicate mild cognitive impairment, and ≤ 20 points may indicate dementia risk

    Time frame: Baseline, month 6

  11. Bone density

    Bone density, lumbar spine bone density (lumbar 2 - lumbar 4) and left femoral neck bone density are examined using the dualenergy X-ray absorptiometry (DXA) method.

    Time frame: Baseline, month 6

  12. Knee joint ultrasound

    Ultrasound was used to examine the knee joint cavity for fluid or synovial hyperplasia and the tendon ligaments and muscles around the knee joint for damage.

    Time frame: Baseline, month 6

  13. Knee injury and osteoarthritis outcome score (KOOS score)

    The KOOS rating includes five independent evaluation dimensions, each calculated separately and converted into a percentage scale (0-100 points, with higher scores indicating better functionality)

    Time frame: Baseline, month 3, month 6

  14. Serum sarcopenia related factors

    Detect serum calcium (Ca), phosphorus (P), serum hydroxyvitamin D (25(OH)D), serum parathyroid hormone (PTH), P-alkaline phosphatase (ALP), serum osteocalcin (OC), serum type 1 pro-collagen N-terminal pre-peptide, serum type 1 collagen cross-linking N-terminal peptide (NTX), and serum anti-tartrate acid phosphatase 5b (TRACP-5b), estradiol (E2), leptin (LP), and so on.

    Time frame: Baseline, month 6

  15. Blood lipid concentration

    Determine the serum levels of blood lipid concentration in the population. Lipid tests include total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C).

    Time frame: Baseline, month 6

  16. Blood glucose concentration

    Blood glucose tests are fasting blood glucose.

    Time frame: Baseline, month 6

  17. Insulin concentration

    Measurement of insulin secretion level.

    Time frame: Baseline, month 6

  18. Inflammation-related biochemical indicators

    Detecting inflammatory cytokine concentration: including TNF-α, IL-1 α, IL-1 β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10 and other inflammatory factors.

    Time frame: month 6

  19. Detection of intestinal flora species, quantity and differentiation level in human population

    The collected feces were subjected to 16S rRNA sequencing technology to detect the diversity of gut microbiota.

    Time frame: month 6

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 16 months is below that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2025
First posted
Jul 3, 2025
StartEst.
Aug 2025
Primary completionEst.
Dec 2026
CompletionEst.
Apr 2027
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07049731
Lead sponsor
Weiwei Ma
Collaborators
Beijing Jishuitan Hospital, Capital Medical University, Capital Medical University, Beijing Friendship Hospital
Responsible party
Weiwei Ma (professor, Capital Medical University) — Sponsor-investigator
First posted
Jul 3, 2025
Start date
Aug 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jul 9, 2025

Study contacts

Weiwei Ma
Contact
weiweima@ccmu.edu.cn
+8615810307505

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion